West Pharmaceutical Services, Inc. (WST), an injectable solutions and service provider, announced on Monday that its Board of Directors has appointed Michel Lagarde to succeed the role of President, CEO and a member of the company's Board of Directors effective on August 31, 2026 as Eric Green, President, Chief Executive Officer and Board Chair will retire from his current role.
Lagarde brings expertise as an Executive Vice President and Chief Operating Officer from Thermo Fisher Scientific.
He also served as a Managing Director at JLL Partners, an equity focused health care service from 2008 to 2016. He joined as the Board of Directors of Vertex Pharmaceuticals in 2023 and is serving as Chair of the Audit and Finance Committee. As a part of the CEO transition, the company has also elected Robert F.Friel, Lead Independent Director as the Board Chair, effective August 31, 2026.
WST closed Monday's trade at $316.3, down 2.02%. In the after-hours the shares are trading up 0.40% to $317.56.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.